In line with the well-established role of metabolism in drug sensitivity in AML and considering the central metabolic functions of PDP1, we aimed to investigate the relevance of PDP1 as a modulator of leukemia response to FLT3 inhibitors. This evidence concerns the gene PDP1 and leukemia.